Hepatitis B e-Antibody Test

Anti-HBe is an antibody made by your immune system in response to the hepatitis B e-antigen (HBeAg), a protein that signals high levels of hepatitis B virus (HBV) replication and infectivity. When the body produces anti-HBe, it usually indicates that viral replication is slowing down and that the infection is becoming less contagious. This change, called “HBeAg seroconversion,” is a key milestone in chronic hepatitis B and often suggests a more stable phase of disease.

The presence of anti-HBe is generally a good sign. In many people with chronic hepatitis B, it means the immune system has started to control the virus, and liver damage is less likely to progress. These individuals often enter what’s called the “inactive carrier state,” where the virus remains in the body but causes little or no liver inflammation. This phase carries a lower risk of cirrhosis (scarring of the liver) and liver cancer, and it is often a goal of antiviral therapy.

However, the picture is more complex in some cases. Certain variants of the hepatitis B virus, especially those with mutations in the precore or core promoter regions, can stop producing HBeAg even though the virus continues to replicate. In these cases, a person may test positive for anti-HBe and still have high levels of viral DNA in their blood, along with ongoing liver inflammation. This condition is known as HBeAg-negative chronic hepatitis B and is now the most common form of chronic hepatitis B worldwide. It requires close monitoring and, in many cases, continued treatment.

Another key feature of anti-HBe is its role in reducing transmission risk. Blood samples from anti-HBe positive individuals are significantly less infectious than those from people who are HBeAg-positive. In pregnant women, having anti-HBe, even if the viral load is high, substantially lowers the risk of passing HBV to the newborn.